Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Am J Hematol Retrieve available abstracts of 370 articles: HTML format

Single Articles

March 2025
1. BRUNO JE, Herne CA, Baran AM, VanDerMeid KR, et al
   Treatment of Relapsed/Refractory CLL Patients With PI3Kdelta Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.
   Am J Hematol. 2025;100:523-526.
   PubMed     Abstract available
   
   
   February 2025
2. SU W, Stricherz M, Martin A, Belsey J, et al
   The Efficacy of Pediatric-Inspired Regimens vs. Hyper-CVAD in the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.
   Am J Hematol. 2025 Feb 13. doi: 10.1002/ajh.27607.
   PubMed     Abstract available
   
   
   
3. SHIMONY S, Stahl M, Stone RM
   Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.
   Am J Hematol. 2025 Feb 12. doi: 10.1002/ajh.27625.
   PubMed     Abstract available
   
   
   
4. CANALI A, Rieu JB, Lapierre L, Bain BJ, et al
   BCR::ABL1-Positive Acute Myeloid Leukemia.
   Am J Hematol. 2025 Feb 11. doi: 10.1002/ajh.27633.
   PubMed    
   
   
   
5. ITONAGA H, Miyazaki Y, Kondo T, Shimazu Y, et al
   Long-Term Survival After Allogeneic Hematopoietic Stem Cell Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia: A Nationwide Retrospective Study by Adult CML/MPN and MDS Working Groups of the Japanese Society for Transplantation
   Am J Hematol. 2025 Feb 11. doi: 10.1002/ajh.27641.
   PubMed    
   
   
   
6. SENAPATI J, Loghavi S, Marvin-Peek J, Garcia-Manero G, et al
   Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies.
   Am J Hematol. 2025 Feb 8. doi: 10.1002/ajh.27628.
   PubMed     Abstract available
   
   
   
7. 
   Correction to "Secondary-Type Mutations Do Not Impact Prognosis in Acute Myelogenous Leukemia AML With Mutated NPM1".
   Am J Hematol. 2025 Feb 5. doi: 10.1002/ajh.27629.
   PubMed    
   
   
   
8. SHIMONY S, Garcia JS
   Sharpening the Tools to Get the Edge on Leukemia.
   Am J Hematol. 2025 Feb 4. doi: 10.1002/ajh.27622.
   PubMed    
   
   
   
9. CHEN EC, Shimony S, Luskin MR, Stone RM, et al
   Biology and Management of Acute Myeloid Leukemia With Mutated NPM1.
   Am J Hematol. 2025 Feb 4. doi: 10.1002/ajh.27600.
   PubMed     Abstract available
   
   
   January 2025
10. MAYER J, Cicatkova P, Kovacova L, Jarosova M, et al
    Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia.
    Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27608.
    PubMed     Abstract available
    
    
    
11. HALLEK M
    Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.
    Am J Hematol. 2025 Jan 28. doi: 10.1002/ajh.27546.
    PubMed     Abstract available
    
    
    
12. WEI Q, Hu S, Loghavi S, Toruner GA, et al
    Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia.
    Am J Hematol. 2025 Jan 27. doi: 10.1002/ajh.27575.
    PubMed     Abstract available
    
    
    
13. ENGELMANN R, Flores-Montero J, Schilperoord-Vermeulen J, Ritgen M, et al
    Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2025 Jan 25. doi: 10.1002/ajh.27604.
    PubMed    
    
    
    
14. BUTLER JT, Yashar WM, Swords R
    Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.
    Am J Hematol. 2025 Jan 7. doi: 10.1002/ajh.27586.
    PubMed     Abstract available
    
    
    
15. KANTARJIAN H, Short NJ, Jain N, Haddad FG, et al
    Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2025 Jan 5. doi: 10.1002/ajh.27576.
    PubMed     Abstract available
    
    
    
16. LUFT T, Gras L, Koster L, Kroger N, et al
    Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT.
    Am J Hematol. 2025;100:38-51.
    PubMed     Abstract available
    
    
    
17. RECHER C, Dumas PY, Berard E, Tavitian S, et al
    Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
    Am J Hematol. 2025;100:23-32.
    PubMed     Abstract available
    
    
    December 2024
18. SENAPATI J, Kantarjian HM, Haddad FG, Short NJ, et al
    Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation.
    Am J Hematol. 2024 Dec 24. doi: 10.1002/ajh.27561.
    PubMed     Abstract available
    
    
    
19. GHOSH N, Eyre TA, Brown JR, Lamanna N, et al
    Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
    Am J Hematol. 2024 Dec 19. doi: 10.1002/ajh.27563.
    PubMed    
    
    
    
20. GANGAT N, Elbeih A, Ghosoun N, McCullough K, et al
    Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
    Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564.
    PubMed     Abstract available
    
    
    
21. CAIROLI R, Gatti A, Grillo G, Stefanucci MR, et al
    Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial.
    Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27547.
    PubMed     Abstract available
    
    
    
22. GUERINEAU H, Cayuela JM, Dulucq S, Tran Quang V, et al
    Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
    Am J Hematol. 2024 Dec 10. doi: 10.1002/ajh.27553.
    PubMed    
    
    
    
23. STUTE N, Koldehoff M
    Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transplantation.
    Am J Hematol. 2024 Dec 3. doi: 10.1002/ajh.27538.
    PubMed    
    
    
    November 2024
24. KIRTEK TJ, Chen W, Harris JC, Bagg A, et al
    Acute Leukemias of Ambiguous Lineage With MDS-Associated Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With MDS-Associated Mutations: A Study From the Bone Marrow Pathology Group.
    Am J Hematol. 2024 Nov 23. doi: 10.1002/ajh.27537.
    PubMed    
    
    
    
25. ROY MOULIK N, Keerthivasagam S, Chatterjee G, Agiwale J, et al
    Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort.
    Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27528.
    PubMed     Abstract available
    
    
    
26. KONUMA T, Kameda K, Morita K, Kondo T, et al
    Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type.
    Am J Hematol. 2024 Nov 20. doi: 10.1002/ajh.27521.
    PubMed     Abstract available
    
    
    
27. SCHMALTER AK, Labopin M, Versluis J, Gallego Hernanz MP, et al
    The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13).
    Am J Hematol. 2024 Nov 18. doi: 10.1002/ajh.27496.
    PubMed     Abstract available
    
    
    
28. LIU H, Xu H, Chi P, Feng Z, et al
    A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph(+) acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study.
    Am J Hematol. 2024 Nov 16. doi: 10.1002/ajh.27516.
    PubMed     Abstract available
    
    
    
29. LUO J, Zhang J, Liu L, Wei R, et al
    Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China.
    Am J Hematol. 2024 Nov 4. doi: 10.1002/ajh.27519.
    PubMed    
    
    
    
30. HEIBLIG M, Gourguechon C, Guilpain P, Bulai-Livideanu C, et al
    Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C-finding treated with midostaurin.
    Am J Hematol. 2024;99:2127-2139.
    PubMed     Abstract available
    
    
    
31. DINARDO CD, Pratz KW, Panayiotidis P, Wei X, et al
    The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2024 Nov 1. doi: 10.1002/ajh.27515.
    PubMed    
    
    
    October 2024
32. SHANKER S, Hasserjian RP, Madanat Y, Weinberg OK, et al
    Impact of myelodysplasia-related mutations on 2022 European LeukemiaNet genetic risk classification in de novo acute myeloid leukemia with normal karyotype.
    Am J Hematol. 2024 Oct 30. doi: 10.1002/ajh.27518.
    PubMed     Abstract available
    
    
    
33. ONIDA F
    Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia.
    Am J Hematol. 2024 Oct 29. doi: 10.1002/ajh.27512.
    PubMed    
    
    
    
34. 
    Abstracts from the 2024 Lymphoma Leukemia and Myeloma Congress October 16-19, 2024.
    Am J Hematol. 2024;99 Suppl 2:S3-S64.
    PubMed    
    
    
    September 2024
35. SRINIVASAN N, Olivier T, Haslam A, Prasad V, et al
    Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial.
    Am J Hematol. 2024 Sep 28. doi: 10.1002/ajh.27477.
    PubMed    
    
    
    
36. TEFFERI A, Fathima S, Alsugair AKA, Aperna F, et al
    PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
    Am J Hematol. 2024 Sep 27. doi: 10.1002/ajh.27492.
    PubMed     Abstract available
    
    
    
37. OZGA M, Nicolet D, Mrozek K, Walker CJ, et al
    White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.
    Am J Hematol. 2024 Sep 16. doi: 10.1002/ajh.27465.
    PubMed    
    
    
    
38. BADAR T, Narra R, Mims AS, Heckman MG, et al
    Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.
    Am J Hematol. 2024 Sep 10. doi: 10.1002/ajh.27475.
    PubMed     Abstract available
    
    
    
39. BAUER K, Hauswirth A, Gleixner KV, Greiner G, et al
    BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
    Am J Hematol. 2024;99:1721-1731.
    PubMed     Abstract available
    
    
    August 2024
40. BARON F, Labopin M, Versluis J, Vydra J, et al
    Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first co
    Am J Hematol. 2024 Aug 31. doi: 10.1002/ajh.27466.
    PubMed     Abstract available
    
    
    
41. ZIMMERMAN MKA, Wilde L
    Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon.
    Am J Hematol. 2024 Aug 28. doi: 10.1002/ajh.27467.
    PubMed    
    
    
    
42. JEN WY, Jabbour E, Short NJ, Issa GC, et al
    A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia.
    Am J Hematol. 2024 Aug 28. doi: 10.1002/ajh.27463.
    PubMed     Abstract available
    
    
    
43. HAZARIKA B, Bain BJ
    Presentation of chronic myeloid leukemia in basophilic blast crisis.
    Am J Hematol. 2024 Aug 23. doi: 10.1002/ajh.27464.
    PubMed    
    
    
    
44. SHEN Q, Jabbour EJ, Tang G, Fang H, et al
    Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia.
    Am J Hematol. 2024 Aug 17. doi: 10.1002/ajh.27462.
    PubMed    
    
    
    
45. LIPTON JH
    Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?
    Am J Hematol. 2024 Aug 14. doi: 10.1002/ajh.27455.
    PubMed    
    
    
    
46. JABBOUR E, Kantarjian H
    Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
    Am J Hematol. 2024 Aug 2. doi: 10.1002/ajh.27443.
    PubMed     Abstract available
    
    
    
47. KANTARJIAN HM, Begna K, Jabbour EJ, Paul S, et al
    Optimal frontline therapy of chronic myeloid leukemia today, and related musings.
    Am J Hematol. 2024 Aug 2. doi: 10.1002/ajh.27445.
    PubMed    
    
    
    
48. SMITH CJ, Ruan GJ, Kluck LA, Maberry M, et al
    BCR-ABL testing in the evaluation of neutrophilia.
    Am J Hematol. 2024;99:1651-1654.
    PubMed    
    
    
    
49. KANTARJIAN HM, Chifotides HT, Haddad FG, Short NJ, et al
    Ponatinib-review of historical development, current status, and future research.
    Am J Hematol. 2024;99:1576-1585.
    PubMed     Abstract available
    
    
    July 2024
50. WILLEMSEN M, Smeets P, de Coninck A
    Isolated peripheral nervous system relapse after allogeneic hematopoietic cell transplantation for T-cell acute lymphoblastic leukemia.
    Am J Hematol. 2024 Jul 30. doi: 10.1002/ajh.27441.
    PubMed    
    
    
    
51. MOLICA S, Allsup D, Giannarelli D
    Network meta-analysis of upfront fixed-duration therapies in chronic lymphocytic leukemia.
    Am J Hematol. 2024 Jul 23. doi: 10.1002/ajh.27437.
    PubMed    
    
    
    
52. LOGHAVI S, Wei Q, Ravandi F, Quesada AE, et al
    Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia.
    Am J Hematol. 2024 Jul 17. doi: 10.1002/ajh.27435.
    PubMed     Abstract available
    
    
    
53. MARVIN-PEEK J, Gilbert JS, Pollyea DA, DiNardo CD, et al
    Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
    Am J Hematol. 2024 Jul 17. doi: 10.1002/ajh.27434.
    PubMed     Abstract available
    
    
    
54. BALEV M, Zibara V, Van Hyfte G, Feld J, et al
    Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse-free survival in acute myeloid leukemia.
    Am J Hematol. 2024 Jul 5. doi: 10.1002/ajh.27429.
    PubMed     Abstract available
    
    
    
55. TU S, Zhou L, Huang R, Zhou X, et al
    Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients.
    Am J Hematol. 2024;99:1437-1440.
    PubMed    
    
    
    
56. PEREZ CARRETERO C, Gonzalez T, Quijada Alamo M, Rigolin GM, et al
    Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis.
    Am J Hematol. 2024 Jul 1. doi: 10.1002/ajh.27421.
    PubMed    
    
    
    June 2024
57. LANCE A, Chiad Z, Seegers SL, Paschall SC, et al
    Hereditary chronic neutrophilic leukemia in a four-generation family without transformation to acute leukemia.
    Am J Hematol. 2024 Jun 27. doi: 10.1002/ajh.27420.
    PubMed     Abstract available
    
    
    
58. VENANZI A, Cardinali V, Perriello V, Albano F, et al
    Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia.
    Am J Hematol. 2024 Jun 22. doi: 10.1002/ajh.27415.
    PubMed    
    
    
    
59. GARCIAZ S, Dumas PY, Bertoli S, Sallman DA, et al
    Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
    Am J Hematol. 2024 Jun 20. doi: 10.1002/ajh.27417.
    PubMed     Abstract available
    
    
    
60. NAGLER A, Ngoya M, Galimard JE, Labopin M, et al
    Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Ac
    Am J Hematol. 2024 Jun 10. doi: 10.1002/ajh.27383.
    PubMed     Abstract available
    
    
    
61. CLAUDIANI S, Chee L, Fernando F, Brown L, et al
    Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations.
    Am J Hematol. 2024;99:1172-1174.
    PubMed     Abstract available
    
    
    May 2024
62. VERONESE L, Bensaber H, Dannus LT, Giannone G, et al
    Molecular landscape of mature B-cell lymphoproliferative disorders with BCL3-translocation: A Groupe Francophone de Cytogenetique Hematologique (GFCH)/French Innovative Leukemia Organization (FILO) study.
    Am J Hematol. 2024 May 30. doi: 10.1002/ajh.27384.
    PubMed    
    
    
    
63. OTHMAN T, Koller P, Tsai NC, Yang D, et al
    Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Am J Hematol. 2024 May 28. doi: 10.1002/ajh.27378.
    PubMed     Abstract available
    
    
    
64. OTHMAN T, Li S, Zhang J, Pourhassan H, et al
    Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Am J Hematol. 2024 May 27. doi: 10.1002/ajh.27365.
    PubMed     Abstract available
    
    
    
65. DEVILLIER R, Galimard JE, Blaise D, Raiola AM, et al
    Peripheral blood stem cell versus bone marrow graft for patients >/=60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of
    Am J Hematol. 2024 May 23. doi: 10.1002/ajh.27343.
    PubMed     Abstract available
    
    
    
66. KOCKEROLS C, Valk PJM, Dulucq S, Nicolini FE, et al
    BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.
    Am J Hematol. 2024 May 20. doi: 10.1002/ajh.27359.
    PubMed    
    
    
    
67. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
    Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
    Am J Hematol. 2024 May 17. doi: 10.1002/ajh.27367.
    PubMed    
    
    
    
68. BEWERSDORF JP, Shimony S, Shallis RM, Liu Y, et al
    Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
    Am J Hematol. 2024 May 15. doi: 10.1002/ajh.27366.
    PubMed    
    
    
    
69. RANAWEERA ARACHCHIGE T, Mendiburu C, Martin A, Fleury C, et al
    Clinical and biological characterization of involvement of nasal-associated lymphoid tissues in chronic lymphocytic leukemia.
    Am J Hematol. 2024 May 10. doi: 10.1002/ajh.27357.
    PubMed    
    
    
    
70. SHOMALI W, Gotlib J
    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2024;99:946-968.
    PubMed     Abstract available
    
    
    
71. CIUREA SO, Kongtim P, Srour S, Chen J, et al
    Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.
    Am J Hematol. 2024;99:890-899.
    PubMed     Abstract available
    
    
    
72. ORVAIN C, Ali N, Othus M, Rodriguez-Arboli E, et al
    Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
    Am J Hematol. 2024;99:862-870.
    PubMed     Abstract available
    
    
    
73. NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al
    Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.
    Am J Hematol. 2024;99:806-815.
    PubMed     Abstract available
    
    
    April 2024
74. YE Y, Labopin M, Gerard S, Yakoub-Agha I, et al
    Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the Europea
    Am J Hematol. 2024 Apr 24. doi: 10.1002/ajh.27342.
    PubMed     Abstract available
    
    
    
75. ZHOU Z, Zhuo N, Zhou Y, Sun C, et al
    Identification of the characteristics and prognostic impact of FUS::ERG and RUNX1::CBFA2T3 fusion genes in adult acute myeloid leukemia patients.
    Am J Hematol. 2024 Apr 23. doi: 10.1002/ajh.27340.
    PubMed    
    
    
    
76. SZUBER N, Orazi A, Tefferi A
    Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
    Am J Hematol. 2024 Apr 21. doi: 10.1002/ajh.27321.
    PubMed     Abstract available
    
    
    
77. SHORT NJ, Jabbour E, Nasr LF, Jain N, et al
    Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
    Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329.
    PubMed    
    
    
    
78. CRAMER P, von Tresckow J, Fink AM, Robrecht S, et al
    Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
    Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304.
    PubMed    
    
    
    
79. MUSICK JO, Williams EK, Fibben KS, Zhang DY, et al
    Redefining hyperviscosity in acute leukemia: Potential implications for red cell transfusions in the microvasculature.
    Am J Hematol. 2024 Apr 4. doi: 10.1002/ajh.27308.
    PubMed     Abstract available
    
    
    
80. KHAN AA, James D, Andresen V, Atkey J, et al
    Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations.
    Am J Hematol. 2024 Apr 3. doi: 10.1002/ajh.27301.
    PubMed    
    
    
    
81. LITZOW MR
    Building a better blinatumomab.
    Am J Hematol. 2024;99:512-514.
    PubMed    
    
    
    
82. HU S, Jabbour EJ, Hu CY, Tang G, et al
    Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive B-ALL and pose a diagnostic challenge.
    Am J Hematol. 2024;99:721-726.
    PubMed    
    
    
    March 2024
83. HADDAD FG, Sasaki K, Issa GC, Jabbour E, et al
    The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia.
    Am J Hematol. 2024 Mar 28. doi: 10.1002/ajh.27307.
    PubMed    
    
    
    
84. TANG H, Jia W, Jia S, Dong R, et al
    A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
    Am J Hematol. 2024 Mar 14. doi: 10.1002/ajh.27289.
    PubMed    
    
    
    
85. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
    Am J Hematol. 2024 Mar 7. doi: 10.1002/ajh.27271.
    PubMed     Abstract available
    
    
    
86. TROUSSARD X, Maitre E, Paillassa J
    Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
    Am J Hematol. 2024 Mar 5. doi: 10.1002/ajh.27240.
    PubMed     Abstract available
    
    
    February 2024
87. MIRVIS E, Sairam S, Vainieri E, Tona F, et al
    Pituitary apoplexy in acute promyelocytic leukemia.
    Am J Hematol. 2024 Feb 29. doi: 10.1002/ajh.27277.
    PubMed    
    
    
    
88. JIANG M, Wang X, Yu M, Jiang S, et al
    Report of IRF2BP1 as a novel partner of RARA in variant acute promyelocytic leukemia.
    Am J Hematol. 2024 Feb 27. doi: 10.1002/ajh.27272.
    PubMed     Abstract available
    
    
    
89. SANDBERG Y, Budel LM, Bain BJ
    Neutrophilic leukemoid reaction or chronic neutrophilic leukemia-not always so simple.
    Am J Hematol. 2024 Feb 23. doi: 10.1002/ajh.27268.
    PubMed    
    
    
    
90. GANGAT N, Tefferi A
    Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
    Am J Hematol. 2024 Feb 20. doi: 10.1002/ajh.27256.
    PubMed     Abstract available
    
    
    
91. BATALLER A, DiNardo CD, Bazinet A, Daver NG, et al
    Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
    Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27236.
    PubMed     Abstract available
    
    
    
92. KITTAI AS, Hang Y, Bhat SA, Clark A, et al
    Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
    Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27241.
    PubMed     Abstract available
    
    
    
93. PRATZ KW, Jonas BA, Pullarkat V, Thirman MJ, et al
    Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27246.
    PubMed     Abstract available
    
    
    
94. AUTORE F, Visentin A, Deodato M, Vitale C, et al
    Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27247.
    PubMed    
    
    
    
95. ABAZA Y, Winer ES, Murthy GSG, Shallis RM, et al
    Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
    Am J Hematol. 2024 Feb 11. doi: 10.1002/ajh.27231.
    PubMed     Abstract available
    
    
    
96. CHEN X, Yuan L, Zhang Y, Wang F, et al
    Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
    Am J Hematol. 2024 Feb 6. doi: 10.1002/ajh.27249.
    PubMed     Abstract available
    
    
    
97. JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al
    Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227.
    PubMed     Abstract available
    
    
    
98. HORNAK T, Mayer J, Cicatkova P, Semerad L, et al
    De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27229.
    PubMed     Abstract available
    
    
    
99. BENESOVA A, De Santis S, Polivkova V, Pecherkova P, et al
    Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232.
    PubMed    
    
    
    
100. KURITA N, Imahashi N, Chiba S, Tanaka M, et al
     Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study.
     Am J Hematol. 2024;99:236-244.
     PubMed     Abstract available
     
     
     
101. GURNARI C, Pascale MR, Vitale A, Diral E, et al
     Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
     Am J Hematol. 2024;99:254-262.
     PubMed     Abstract available
     
     
     
102. DINARDO CD
     Toward an improved understanding of hypomethylating agent and venetoclax therapies.
     Am J Hematol. 2024;99:152-154.
     PubMed    
     
     
     
103. BRUNNER AM, Esteve J, Porkka K, Knapper S, et al
     Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
     Am J Hematol. 2024;99:E32-E36.
     PubMed     Abstract available
     
     
     January 2024
104. CAMPANELLA A, Capasso A, Heltai S, Taccetti C, et al
     Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
     Am J Hematol. 2024 Jan 24. doi: 10.1002/ajh.27218.
     PubMed     Abstract available
     
     
     
105. IM A, Quann K, Agha M, Raptis A, et al
     Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
     Am J Hematol. 2024 Jan 22. doi: 10.1002/ajh.27212.
     PubMed     Abstract available
     
     
     
106. VARDELL VA, Ermann DA, Fitzgerald L, Shah H, et al
     T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments.
     Am J Hematol. 2024 Jan 19. doi: 10.1002/ajh.27205.
     PubMed     Abstract available
     
     
     
107. 
     Correction to "Analysis of 60 Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Treated with CD7-targeted Chimeric Antigen Receptor-T Cell Therapy".
     Am J Hematol. 2024 Jan 15. doi: 10.1002/ajh.27217.
     PubMed    
     
     
     
108. BARON F, Efficace F, Cannella L, Stevens-Kroef M, et al
     Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
     Am J Hematol. 2024 Jan 4. doi: 10.1002/ajh.27196.
     PubMed     Abstract available
     
     
     
109. MOUKALLED N, Labopin M, Versluis J, Socie G, et al
     Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Le
     Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27187.
     PubMed     Abstract available
     
     
     
110. PELLAND-MARCOTTE MC, Kulkarni K, Tran TH, Stammers D, et al
     Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C.
     Am J Hematol. 2024 Jan 2. doi: 10.1002/ajh.27171.
     PubMed     Abstract available
     
     
     
111. SPONSEILER I, Bandian AM, Pusic P, Lion T, et al
     Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias.
     Am J Hematol. 2024;99:E9-E11.
     PubMed    
     
     
     
112. TEFFERI A, Abdelmagid M, Al-Kali A, Patnaik M, et al
     Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases.
     Am J Hematol. 2024;99:21-27.
     PubMed     Abstract available
     
     
     December 2023
113. MOLICA S, Shanafelt TD, Allsup D, Giannarelli D, et al
     Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population.
     Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27182.
     PubMed     Abstract available
     
     
     
114. KARRAR O, Abdelmagid M, Rana M, Iftikhar M, et al
     Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
     Am J Hematol. 2023 Dec 15. doi: 10.1002/ajh.27180.
     PubMed     Abstract available
     
     
     
115. GANGAT N, Karrar O, Iftikhar M, McCullough K, et al
     Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
     Am J Hematol. 2023 Dec 10. doi: 10.1002/ajh.27138.
     PubMed     Abstract available
     
     
     
116. JOSHI SK, Pittsenbarger J, Kennedy VE, Peretz CAC, et al
     The FLT3(N701K) mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
     Am J Hematol. 2023;98:E364-E368.
     PubMed    
     
     
     
117. OLIVA-ARIZA G, Fuentes-Herrero B, Lecrevisse Q, Carbonell C, et al
     Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis.
     Am J Hematol. 2023;98:1909-1922.
     PubMed     Abstract available
     
     
     November 2023
118. VALENT P
     Clinical impact of cytomorphology in mast cell leukemia.
     Am J Hematol. 2023 Nov 6. doi: 10.1002/ajh.27146.
     PubMed    
     
     
     
119. BATALLER A, Loghavi S, Gerstein Y, Bazinet A, et al
     Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
     Am J Hematol. 2023;98:1780-1790.
     PubMed     Abstract available
     
     
     October 2023
120. GHERGUS D, Martin M, Knapp AM, Delmotte F, et al
     Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?
     Am J Hematol. 2023 Oct 19. doi: 10.1002/ajh.27137.
     PubMed     Abstract available
     
     
     
121. SALIBA RM, Kanakry CG, Gadalla S, Kebriaei P, et al
     Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age.
     Am J Hematol. 2023 Oct 18. doi: 10.1002/ajh.27126.
     PubMed     Abstract available
     
     
     
122. KITTAI AS, Skarbnik A, Miranda M, Yong ASM, et al
     A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.
     Am J Hematol. 2023 Oct 9. doi: 10.1002/ajh.27110.
     PubMed    
     
     
     
123. ZHANG L, Yang X, Ge X, Li B, et al
     CMSS1::FLT1 rearrangement leads to ligand-independent activation of FLT1 signaling in acute myeloid leukemia.
     Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27108.
     PubMed    
     
     
     
124. SUNG MT, Chen LH, Chiang YW, Jhuang JY, et al
     Deciphering clonal architecture and evolutionary dynamics of secondary acute myeloid leukemia and donor-derived myelodysplastic syndrome using single-cell multi-omics analysis.
     Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27121.
     PubMed    
     
     
     
125. HAZARIKA B, Bain BJ
     Pseudo-Chediak-Higashi anomaly in acute myeloid leukemia.
     Am J Hematol. 2023 Oct 4. doi: 10.1002/ajh.27114.
     PubMed    
     
     
     
126. HIRABAYASHI S, Kondo T, Nishiwaki S, Mizuta S, et al
     Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph(+) ALL: A retrospective nationwide study.
     Am J Hematol. 2023;98:1606-1618.
     PubMed     Abstract available
     
     
     
127. CALABRESI L, Carretta C, Romagnoli S, Rotunno G, et al
     Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
     Am J Hematol. 2023;98:1520-1531.
     PubMed     Abstract available
     
     
     
128. 
     Abstracts from the 2023 Lymphoma, Leukemia and Myeloma Congress October 18-21, 2023.
     Am J Hematol. 2023;98 Suppl 5:S3-S57.
     PubMed    
     
     
     September 2023
129. VISENTIN A, Chatzikonstantinou T, Scarfo L, Kapetanakis A, et al
     The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
     Am J Hematol. 2023 Sep 29. doi: 10.1002/ajh.27093.
     PubMed     Abstract available
     
     
     
130. HADDAD FG, Short NJ
     Treatment discontinuation in chronic myeloid leukemia: When, how, and why?
     Am J Hematol. 2023 Sep 27. doi: 10.1002/ajh.27100.
     PubMed    
     
     
     
131. ZHANG X, Yang J, Li J, Qiu L, et al
     Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
     Am J Hematol. 2023 Sep 23. doi: 10.1002/ajh.27094.
     PubMed     Abstract available
     
     
     
132. TEFFERI A, Pardanani A, Al-Kali A, Alkhateeb H, et al
     Mast cell cytomorphology and treatment outcome in mast cell leukemia.
     Am J Hematol. 2023 Sep 21. doi: 10.1002/ajh.27105.
     PubMed    
     
     
     
133. ANIL J, Alnemri A, Lytle A, Lockhart B, et al
     Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy in B-acute lymphoblastic leukemia.
     Am J Hematol. 2023 Sep 18. doi: 10.1002/ajh.27098.
     PubMed     Abstract available
     
     
     
134. VON ASMUTH EGJ, Lankester AC, Putter H
     Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias?
     Am J Hematol. 2023 Sep 15. doi: 10.1002/ajh.27083.
     PubMed    
     
     
     
135. PATEL PC, Ball S, Jain AG, Wang C, et al
     Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
     Am J Hematol. 2023 Sep 13. doi: 10.1002/ajh.27092.
     PubMed     Abstract available
     
     
     
136. PARDANANI A, Tefferi A, Al-Kali A, Patnaik M, et al
     Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
     Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27089.
     PubMed     Abstract available
     
     
     
137. NATH K, Lee J, Elko TA, Levy L, et al
     Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
     Am J Hematol. 2023 Sep 9. doi: 10.1002/ajh.27084.
     PubMed     Abstract available
     
     
     
138. FANG H, Medeiros LJ, Wang W
     Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?
     Am J Hematol. 2023 Sep 8. doi: 10.1002/ajh.27085.
     PubMed    
     
     
     
139. RAVANDI F, Cloos J, Buccisano F, Dillon R, et al
     Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
     Am J Hematol. 2023 Sep 6. doi: 10.1002/ajh.27087.
     PubMed     Abstract available
     
     
     
140. ZHOU JY, Wang S, Yuan HL, Xu YJ, et al
     Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML.
     Am J Hematol. 2023;98:1394-1406.
     PubMed     Abstract available
     
     
     
141. TEFFERI A, Barbui T
     Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
     Am J Hematol. 2023;98:1465-1487.
     PubMed     Abstract available
     
     
     August 2023
142. ZAMBROTTA GPM, Nicolini FE, Assouline S, Busque L, et al
     Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study.
     Am J Hematol. 2023 Aug 30. doi: 10.1002/ajh.27073.
     PubMed     Abstract available
     
     
     
143. KADIA TM, Ravandi F, Molica M, Bataller A, et al
     Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
     Am J Hematol. 2023 Aug 27. doi: 10.1002/ajh.27054.
     PubMed     Abstract available
     
     
     
144. KOSYDAR SR, Parikh SA, Lester SC, Rabe KG, et al
     Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment.
     Am J Hematol. 2023 Aug 24. doi: 10.1002/ajh.27060.
     PubMed    
     
     
     
145. GARCIA-MANERO G
     Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
     Am J Hematol. 2023;98:1307-1325.
     PubMed     Abstract available
     
     
     
146. WANG SA, Orazi A, Gotlib J, Reiter A, et al
     The international consensus classification of eosinophilic disorders and systemic mastocytosis.
     Am J Hematol. 2023;98:1286-1306.
     PubMed     Abstract available
     
     
     
147. ZINI G, Bennett JM
     ICC-2022 versus WHO-2022 classification systems for acute leukemias and myeloid neoplasms: The perspective from two classical morphologists.
     Am J Hematol. 2023;98:E209-E211.
     PubMed    
     
     
     
148. SHORT NJ, Jabbour E, Macaron W, Ravandi F, et al
     Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
     Am J Hematol. 2023;98:1196-1203.
     PubMed     Abstract available
     
     
     
149. JELLOUL FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, et al
     DDX41 mutations in patients with non-myeloid hematologic neoplasms.
     Am J Hematol. 2023;98:E193-E196.
     PubMed    
     
     
     July 2023
150. HADDAD FG, Sasaki K, Bidikian A, Issa GC, et al
     Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
     Am J Hematol. 2023 Jul 23. doi: 10.1002/ajh.27037.
     PubMed     Abstract available
     
     
     
151. BRADY MT, Laniewski N, Strawderman M, Chu CC, et al
     Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.
     Am J Hematol. 2023 Jul 23. doi: 10.1002/ajh.27038.
     PubMed    
     
     
     
152. ZUNA J, Hovorkova L, Krotka J, Winkowska L, et al
     Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?
     Am J Hematol. 2023 Jul 14. doi: 10.1002/ajh.27022.
     PubMed    
     
     
     
153. LOSCOCCO GG, Ascani S, Mannelli F, Zanelli M, et al
     Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
     Am J Hematol. 2023 Jul 12. doi: 10.1002/ajh.27026.
     PubMed    
     
     
     
154. PARDANANI A
     Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
     Am J Hematol. 2023;98:1097-1116.
     PubMed     Abstract available
     
     
     
155. FALINI B, Martelli MP, Brunetti L, Gjertsen BT, et al
     The NPM1 mutant defines AML irrespective of blast count.
     Am J Hematol. 2023;98:E187-E189.
     PubMed    
     
     
     June 2023
156. VISENTIN A, Mauro FR, Scarfo L, Gentile M, et al
     Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
     Am J Hematol. 2023 Jun 29. doi: 10.1002/ajh.27009.
     PubMed    
     
     
     
157. NAKA R, Kondo T, Nishikubo M, Muranushi H, et al
     Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
     Am J Hematol. 2023 Jun 28. doi: 10.1002/ajh.27012.
     PubMed    
     
     
     
158. KANTARJIAN HM, Tefferi A
     Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress.
     Am J Hematol. 2023 Jun 26. doi: 10.1002/ajh.27007.
     PubMed    
     
     
     
159. HORST HA, Zugmaier G, Martinelli G, Mergen N, et al
     CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis.
     Am J Hematol. 2023 Jun 22. doi: 10.1002/ajh.26988.
     PubMed    
     
     
     
160. BAZINET A, Kantarjian H, Arani N, Popat U, et al
     Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
     Am J Hematol. 2023 Jun 19. doi: 10.1002/ajh.26997.
     PubMed     Abstract available
     
     
     
161. MATTHEWS AH, Perl AE, Luger SM, Gill SI, et al
     Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
     Am J Hematol. 2023 Jun 19. doi: 10.1002/ajh.26991.
     PubMed     Abstract available
     
     
     
162. FALINI B
     NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
     Am J Hematol. 2023 Jun 15. doi: 10.1002/ajh.26989.
     PubMed     Abstract available
     
     
     
163. SALIBA AN, Foa R
     Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing.
     Am J Hematol. 2023 Jun 14. doi: 10.1002/ajh.26993.
     PubMed    
     
     
     
164. JADI O, Tang H, Olsen K, Vensko S, et al
     Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantation.
     Am J Hematol. 2023;98:940-950.
     PubMed     Abstract available
     
     
     
165. TANG Y, Zhang Z, Liu S, Yao Y, et al
     Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation.
     Am J Hematol. 2023;98:881-889.
     PubMed     Abstract available
     
     
     
166. FENU EM, Margolskee E, Pillai V
     Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy.
     Am J Hematol. 2023 Jun 1. doi: 10.1002/ajh.26983.
     PubMed    
     
     
     May 2023
167. GIRARD S, Lours C
     Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
     Am J Hematol. 2023 May 25. doi: 10.1002/ajh.26969.
     PubMed    
     
     
     
168. ROTBAIN EC, Allmer C, Rostgaard K, Andersen MA, et al
     Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia.
     Am J Hematol. 2023 May 22. doi: 10.1002/ajh.26964.
     PubMed     Abstract available
     
     
     
169. ISHIDA H, Shimada H, Tanizawa A, Shimazu Y, et al
     Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era.
     Am J Hematol. 2023 May 12. doi: 10.1002/ajh.26959.
     PubMed     Abstract available
     
     
     
170. DAVER NG, Iqbal S, Huang J, Renard C, et al
     Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.
     Am J Hematol. 2023 May 4. doi: 10.1002/ajh.26941.
     PubMed     Abstract available
     
     
     
171. YANG S, Zhang X, Gale RP, Du X, et al
     Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
     Am J Hematol. 2023 May 2. doi: 10.1002/ajh.26943.
     PubMed    
     
     
     
172. IVANOV D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, et al
     Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
     Am J Hematol. 2023;98:770-783.
     PubMed     Abstract available
     
     
     
173. HUNTINGTON SF, Schuster SJ, Ding W, Koehler AB, et al
     DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
     Am J Hematol. 2023;98:739-749.
     PubMed     Abstract available
     
     
     
174. MARCOUX C, Marin D, Ramdial J, AlAtrash G, et al
     Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS.
     Am J Hematol. 2023;98:712-719.
     PubMed     Abstract available
     
     
     April 2023
175. FAN BE, Chen DTY, Ponnudurai K, Abdul Latiff STB, et al
     Artificial intelligence generated leukemia cell images.
     Am J Hematol. 2023 Apr 29. doi: 10.1002/ajh.26942.
     PubMed    
     
     
     
176. VARDELL VA, Ermann DA, Fitzgerald LA, Shah HR, et al
     Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia.
     Am J Hematol. 2023 Apr 20. doi: 10.1002/ajh.26937.
     PubMed     Abstract available
     
     
     
177. MORABITO F, Tripepi G, Mauro FR, Laurenti L, et al
     The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
     Am J Hematol. 2023 Apr 17. doi: 10.1002/ajh.26927.
     PubMed    
     
     
     
178. FALINI B, Martelli MP, Brunetti L
     Mutant NPM1: Nuclear export and the mechanism of leukemogenesis.
     Am J Hematol. 2023;98:550-552.
     PubMed    
     
     
     
179. HAMPEL PJ, Parikh SA
     BTKi bonanza in CLL/SLL: Sorting out the differences.
     Am J Hematol. 2023;98:556-559.
     PubMed    
     
     
     
180. TEFFERI A, Bacigalup A
     Blast phase myeloproliferative neoplasm: Transplant to the rescue.
     Am J Hematol. 2023;98:553-555.
     PubMed    
     
     
     
181. ORTI G, Gras L, Zinger N, Finazzi MC, et al
     Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantat
     Am J Hematol. 2023;98:628-638.
     PubMed     Abstract available
     
     
     March 2023
182. ROSE A, Zhang L, Jain AG, Poovathukaran Babu A, et al
     Delineation of Clinical Course, Outcomes, and Prognostic Factors in Patients with T-cell Prolymphocytic Leukemia.
     Am J Hematol. 2023 Mar 25. doi: 10.1002/ajh.26918.
     PubMed     Abstract available
     
     
     
183. BACHELOT A, Bouvier A, Riou J, Thepot S, et al
     Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: assessment of different risk scores.
     Am J Hematol. 2023 Mar 25. doi: 10.1002/ajh.26917.
     PubMed     Abstract available
     
     
     
184. 
     Corrigendum to "Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia".
     Am J Hematol. 2023 Mar 24. doi: 10.1002/ajh.26894.
     PubMed    
     
     
     
185. GIPE N, Leung N, Lasho T, Mangaonkar A, et al
     Spectrum of renal pathological findings in patients with chronic myelomonocytic leukemia and kidney injury.
     Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26902.
     PubMed    
     
     
     
186. ALDOSS I, Afkhami M, Yang D, Gu Z, et al
     High Response Rates and Transition to Transplant after Novel Targeted and Cellular Therapies in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia with Philadelphia-Like Fusions.
     Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26908.
     PubMed     Abstract available
     
     
     
187. QIU KY, Wang JY, Huang LB, Li CG, et al
     Vincristine and Dexamethasone Pulses in Addition to Maintenance Therapy Among Pediatric Acute Lymphoblastic Leukemia(GD-ALL-2008): an Open-label, Multicentre, Randomized, Phase III Clinical Trial.
     Am J Hematol. 2023 Mar 6. doi: 10.1002/ajh.26910.
     PubMed     Abstract available
     
     
     
188. DESIKAN SP, Senapati J, Jabbour E, Abuasab T, et al
     Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia.
     Am J Hematol. 2023 Mar 6. doi: 10.1002/ajh.26907.
     PubMed    
     
     
     
189. KATODRITOU E, Kastritis E, Dalampira D, Delimpasi S, et al
     Improved Survival of Patients with Primary Plasma Cell Leukemia with VRd or Daratumumab-based Quadruplets: A Multicenter Study by the Greek Myeloma Study Group.
     Am J Hematol. 2023 Mar 4. doi: 10.1002/ajh.26891.
     PubMed     Abstract available
     
     
     
190. LO MY, Tsai XC, Lin CC, Tien FM, et al
     Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
     Am J Hematol. 2023 Mar 2. doi: 10.1002/ajh.26892.
     PubMed     Abstract available
     
     
     
191. YANG YT, Yao CY, Chiu PJ, Kao CJ, et al
     Evaluation of the clinical significance of global mRNA alternative splicing in patients with acute myeloid leukemia.
     Am J Hematol. 2023 Mar 1. doi: 10.1002/ajh.26893.
     PubMed     Abstract available
     
     
     February 2023
192. EPPERLA N, Zhao Q, Anghelina M, Neal J, et al
     Impact of sex on outcomes in patients with Hairy cell leukemia. An HCL Patient Data Registry analysis.
     Am J Hematol. 2023 Feb 20. doi: 10.1002/ajh.26881.
     PubMed    
     
     
     
193. BADAT M, Sivaguru G, Bain BJ
     Ophthalmic presentation of chronic myeloid leukemia in two adolescents.
     Am J Hematol. 2023 Feb 16. doi: 10.1002/ajh.26884.
     PubMed    
     
     
     
194. LEE BJ, Griffin SP, Doh J, Kongtim P, et al
     Timing of Intrathecal Chemotherapy and Blinatumomab Impacts Neurotoxicity in Acute Lymphoblastic Leukemia.
     Am J Hematol. 2023 Feb 16. doi: 10.1002/ajh.26880.
     PubMed    
     
     
     
195. MEJIA SALDARRIAGA M, Alhomoud M, Roboz G, Allan JN, et al
     Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia.
     Am J Hematol. 2023 Feb 13. doi: 10.1002/ajh.26878.
     PubMed    
     
     
     
196. ANTHERIEU G, Donzel M, Balme B, Traverse-Glehen A, et al
     Chronic myelomonocytic leukemia transdifferenciation landscape: from histiocytosis to blastic plasmacytoid dendritic cell neoplasm.
     Am J Hematol. 2023 Feb 13. doi: 10.1002/ajh.26876.
     PubMed    
     
     
     
197. ZEIDAN AM, Borate U, Pollyea DA, Brunner AM, et al
     A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
     Am J Hematol. 2023;98:272-281.
     PubMed     Abstract available
     
     
     
198. HERGOTT CB, Dal Cin P, Hornick JL, Winer ES, et al
     Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion.
     Am J Hematol. 2023;98:365-367.
     PubMed    
     
     
     January 2023
199. WALIA A, Prasad V
     Is it time to reconsider molecular response milestones in chronic myeloid leukemia?
     Am J Hematol. 2023 Jan 28. doi: 10.1002/ajh.26867.
     PubMed    
     
     
     
200. KIM MS, Prasad V
     Front-line chronic lymphocytic leukemia: The role of chemoimmunotherapy.
     Am J Hematol. 2023 Jan 26. doi: 10.1002/ajh.26864.
     PubMed    
     
     
     
201. ALDOSS I, Shah BD, Park JH, Muffly L, et al
     Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
     Am J Hematol. 2023 Jan 24. doi: 10.1002/ajh.26853.
     PubMed     Abstract available
     
     
     
202. XU W, Zhou K, Wang T, Yang S, et al
     Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
     Am J Hematol. 2023 Jan 22. doi: 10.1002/ajh.26826.
     PubMed     Abstract available
     
     
     
203. JABBOUR E, Sasaki K, Haddad FG, Issa GC, et al
     The Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line BCR::ABL1 Tyrosine Kinase Inhibitors.
     Am J Hematol. 2023 Jan 22. doi: 10.1002/ajh.26852.
     PubMed     Abstract available
     
     
     
204. WEI AH, Dohner H, Sayar H, Ravandi F, et al
     Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
     Am J Hematol. 2023 Jan 19. doi: 10.1002/ajh.26847.
     PubMed    
     
     
     
205. CANDONI A, Lazzarotto D, Papayannidis C, Piccini M, et al
     PROSPECTIVE MULTICENTER STUDY ON INFECTIOUS COMPLICATIONS AND CLINICAL OUTCOME OF 230 UNFIT ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING FIRST-LINE THERAPY WITH HYPOMETHYLATING AGENTS ALONE OR IN COMBINATION WITH VENETOCLAX.
     Am J Hematol. 2023 Jan 18. doi: 10.1002/ajh.26846.
     PubMed    
     
     
     
206. GIEBEL S, Labopin M, Schroeder T, Swoboda R, et al
     Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Pa
     Am J Hematol. 2023 Jan 10. doi: 10.1002/ajh.26825.
     PubMed     Abstract available
     
     
     
207. AL-KALI A, Tibes R, Atherton P, Palmer J, et al
     A Phase II Study of Combination Daunorubicin, Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia with KIT Expression.
     Am J Hematol. 2023 Jan 9. doi: 10.1002/ajh.26831.
     PubMed     Abstract available
     
     
     
208. BIDIKIAN A, Jabbour E, Issa GC, Short NJ, et al
     Chronic Myeloid Leukemia Without Major Molecular Response After 2 Years of Treatment with Tyrosine Kinase Inhibitor.
     Am J Hematol. 2023 Jan 6. doi: 10.1002/ajh.26836.
     PubMed     Abstract available
     
     
     
209. GURU MURTHY GS, Logan BR, Bo-Subait S, Beitinjaneh A, et al
     Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.
     Am J Hematol. 2023 Jan 6. doi: 10.1002/ajh.26834.
     PubMed     Abstract available
     
     
     
210. FALINI B, Martelli MP
     Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.
     Am J Hematol. 2023 Jan 5. doi: 10.1002/ajh.26812.
     PubMed     Abstract available
     
     
     
211. PATNAIK MM, Tefferi A
     Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
     Am J Hematol. 2023 Jan 4. doi: 10.1002/ajh.26828.
     PubMed     Abstract available
     
     
     
212. KANTARJIAN H, Short NJ, Jain N, Sasaki K, et al
     Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
     Am J Hematol. 2023 Jan 4. doi: 10.1002/ajh.26816.
     PubMed     Abstract available
     
     
     
213. MARTINO G, Quintini M, Martelli MP, Ascani S, et al
     Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia - aCML).
     Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26817.
     PubMed    
     
     
     
214. SHIMONY S, Stahl M, Stone RM
     Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification and management.
     Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26822.
     PubMed     Abstract available
     
     
     
215. HAZARIKA B, Bain BJ
     Granular B lymphoblastic leukemia.
     Am J Hematol. 2023;98:210-211.
     PubMed    
     
     
     
216. THIELE J, Kvasnicka HM, Orazi A, Gianelli U, et al
     The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
     Am J Hematol. 2023;98:166-179.
     PubMed     Abstract available
     
     
     
217. LEE WH, Lin CC, Tsai CH, Tien FM, et al
     Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
     Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26799.
     PubMed     Abstract available
     
     
     
218. GRAF I, Greiner G, Marculescu R, Gleixner KV, et al
     N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.
     Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26805.
     PubMed     Abstract available
     
     
     
219. LIU H, Huang F, Zhang Y, Wu M, et al
     Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
     Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26800.
     PubMed     Abstract available
     
     
     December 2022
220. ARBER DA, Hasserjian RP, Orazi A
     Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia.
     Am J Hematol. 2022 Dec 24. doi: 10.1002/ajh.26820.
     PubMed    
     
     
     
221. SENAPATI J, Abuasab T, Haddad FG, Ravandi F, et al
     Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
     Am J Hematol. 2022 Dec 24. doi: 10.1002/ajh.26811.
     PubMed    
     
     
     
222. SALIBA AN, Foa R
     The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: giant strides and ongoing challenges.
     Am J Hematol. 2022 Dec 20. doi: 10.1002/ajh.26813.
     PubMed    
     
     
     
223. KWON A, Fuda F, Gagan J, John S, et al
     Rare circulating lymphoblasts with striking eosinophilia: A rare case of B lymphoblastic leukemia with PAX5::ZCCHC7.
     Am J Hematol. 2022 Dec 12. doi: 10.1002/ajh.26795.
     PubMed    
     
     
     
224. PASVOLSKY O, Saliba RM, Ledesma C, Popat UR, et al
     Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission.
     Am J Hematol. 2022 Dec 11. doi: 10.1002/ajh.26789.
     PubMed    
     
     
     November 2022
225. RADICH J
     Allogeneic transplantation for chronic myeloid leukemia: I'm not dead yet!
     Am J Hematol. 2022 Nov 24. doi: 10.1002/ajh.26790.
     PubMed    
     
     
     
226. WIECZOREK M, Labopin M, Castagna L, Brissot E, et al
     Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT.
     Am J Hematol. 2022 Nov 18. doi: 10.1002/ajh.26782.
     PubMed    
     
     
     
227. LEVI S, Bronstein Y, Goldschmidt N, Morabito F, et al
     Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
     Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26779.
     PubMed    
     
     
     
228. WOYACH JA
     Management of relapsed/refractory Chronic Lymphocytic Leukemia.
     Am J Hematol. 2022;97 Suppl 2:S11-S18.
     PubMed     Abstract available
     
     
     
229. ARONSON JH, Skanland SS, Roeker LE, Thompson MC, et al
     Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).
     Am J Hematol. 2022;97 Suppl 2:S19-S25.
     PubMed     Abstract available
     
     
     
230. KUTSCH N, Fink AM, Fischer K
     Management of front line chronic lymphocytic leukemia.
     Am J Hematol. 2022;97 Suppl 2:S3-S10.
     PubMed     Abstract available
     
     
     
231. CHIUSOLO P, Marchetti C, Rossi M, Minnella G, et al
     A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer.
     Am J Hematol. 2022;97:E400-E403.
     PubMed    
     
     
     
232. MCVINNIE K, Innes A, Nadal-Melsio E, Atta M, et al
     A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.
     Am J Hematol. 2022;97:1491-1494.
     PubMed    
     
     
     October 2022
233. ALDULESCU M, Leuer K, Jennings LJ, Yap KL, et al
     Lineage switch from acute myeloid leukemia to B-lymphoblastic lymphoma with acquired PIK3R1 loss-of-function mutation.
     Am J Hematol. 2022 Oct 26. doi: 10.1002/ajh.26770.
     PubMed    
     
     
     
234. CHALANDON Y, Sbianchi G, Gras L, Koster L, et al
     Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
     Am J Hematol. 2022 Oct 20. doi: 10.1002/ajh.26764.
     PubMed     Abstract available
     
     
     
235. STAHL M, Derkach A, Farnoud N, Bewersdorf JP, et al
     Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
     Am J Hematol. 2022 Oct 17. doi: 10.1002/ajh.26757.
     PubMed     Abstract available
     
     
     
236. WANG Q, Cai WZ, Wang QR, Zhu MQ, et al
     Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia.
     Am J Hematol. 2022 Oct 11. doi: 10.1002/ajh.26758.
     PubMed     Abstract available
     
     
     
237. KITTAI AS, Huang Y, Beckwith KA, Bhat SA, et al
     Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
     Am J Hematol. 2022 Oct 10. doi: 10.1002/ajh.26755.
     PubMed     Abstract available
     
     
     
238. LANZA L, Koroveshi B, Barducchi F, Lorenzo A, et al
     A new diagnosis of monoclonal B-cell lymphocytosis with cytoplasmic inclusions in a patient with COVID-19.
     Am J Hematol. 2022;97:1372-1373.
     PubMed    
     
     
     
239. 
     Abstracts from the 2022 Lymphoma, Leukemia and Myeloma Congress October 18-22, 2022.
     Am J Hematol. 2022;97 Suppl 3:S3-S40.
     PubMed    
     
     
     September 2022
240. RADKIEWICZ C, Bruchfeld JB, Weibull CE, Jeppesen ML, et al
     Sex differences in lymphoma incidence and mortality by subtype: a population-based study.
     Am J Hematol. 2022 Sep 30. doi: 10.1002/ajh.26744.
     PubMed     Abstract available
     
     
     
241. RIVERA D, Kim K, Kanagal-Shamanna R, Borthakur G, et al
     Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes.
     Am J Hematol. 2022 Sep 18. doi: 10.1002/ajh.26731.
     PubMed     Abstract available
     
     
     
242. ZIPPER R, Fong V, Toker M, Reddy N, et al
     Neutrophilic Eccrine Hidradenitis in a pediatric patient with Acute Myeloid Leukemia.
     Am J Hematol. 2022 Sep 16. doi: 10.1002/ajh.26733.
     PubMed    
     
     
     
243. WRIGHT MF, Pozdnyakova O, Hasserjian RP, Aggarwal N, et al
     Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1.
     Am J Hematol. 2022 Sep 15. doi: 10.1002/ajh.26730.
     PubMed    
     
     
     
244. VENUGOPAL S, DiNardo CD, Loghavi S, Qiao W, et al
     Differential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia.
     Am J Hematol. 2022 Sep 10. doi: 10.1002/ajh.26724.
     PubMed     Abstract available
     
     
     
245. LEE BJ, Griffin SP, Doh J, Chan A, et al
     CD19-Directed Immunotherapy Use in KMT2A-Rearranged Acute Leukemia: A Case Report and Literature Review of Increased Lymphoid to Myeloid Lineage Switch.
     Am J Hematol. 2022 Sep 3. doi: 10.1002/ajh.26713.
     PubMed    
     
     
     
246. FALINI B
     Acute myeloid leukemia risk models: Where do we stand?
     Am J Hematol. 2022;97:1124-1126.
     PubMed    
     
     
     August 2022
247. PRATZ KW, DiNardo CD, Selleslag D, Li J, et al
     Postremission cytopenia management in patients with AML treated with venetoclax and azacitidine in VIALE-A.
     Am J Hematol. 2022 Aug 30. doi: 10.1002/ajh.26692.
     PubMed    
     
     
     
248. JONAS BA, DiNardo C, Fracchiolla N, Pristupa A, et al
     Use of CYP3Ai and impact on outcomes in patients with AML treated with venetoclax plus azacitidine in the VIALE-A study.
     Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26707.
     PubMed    
     
     
     
249. BORTHAKUR G, Ravandi F, Patel K, Wang X, et al
     Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD And
     Am J Hematol. 2022 Aug 26. doi: 10.1002/ajh.26700.
     PubMed     Abstract available
     
     
     
250. SHORT NJ, Macaron W, Kadia T, Dinardo C, et al
     Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience MRD recurrence following MRD-negative remission.
     Am J Hematol. 2022 Aug 24. doi: 10.1002/ajh.26698.
     PubMed    
     
     
     
251. TEFFERI A, Begna KH, McCullough KB
     Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day).
     Am J Hematol. 2022 Aug 22. doi: 10.1002/ajh.26695.
     PubMed    
     
     
     
252. LACHOWIEZ CA, Reville PK, Kantarjian H, Jabbour E, et al
     Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
     Am J Hematol. 2022 Aug 22. doi: 10.1002/ajh.26694.
     PubMed     Abstract available
     
     
     
253. JABBOUR E, Sasaki K, Haddad FG, Issa GC, et al
     Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
     Am J Hematol. 2022 Aug 13. doi: 10.1002/ajh.26689.
     PubMed     Abstract available
     
     
     
254. KANTARJIAN HM, Jabbour E, Deininger M, Abruzzese E, et al
     Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
     Am J Hematol. 2022 Aug 12. doi: 10.1002/ajh.26686.
     PubMed     Abstract available
     
     
     
255. SHAH MV, Chhetri R, Dholakia R, Kok CH, et al
     Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
     Am J Hematol. 2022;97:1013-1022.
     PubMed     Abstract available
     
     
     July 2022
256. SHORT NJ, Kantarjian H
     Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Past Discoveries and Future Directions.
     Am J Hematol. 2022 Jul 24. doi: 10.1002/ajh.26667.
     PubMed     Abstract available
     
     
     
257. HERRMANN L, Bischof L, Backhaus D, Brauer D, et al
     Outcome prediction by the knowledge bank approach in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
     Am J Hematol. 2022 Jul 8. doi: 10.1002/ajh.26653.
     PubMed    
     
     
     
258. PETER B, Eisenwort G, Sadovnik I, Bauer K, et al
     BRD4 Degradation Blocks Expression of MYC and Multiple Forms of Stem Cell Resistance in Ph(+) Chronic Myeloid Leukemia.
     Am J Hematol. 2022 Jul 6. doi: 10.1002/ajh.26650.
     PubMed     Abstract available
     
     
     
259. BADAR T, Atallah E, Shallis RM, Goldberg AD, et al
     Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
     Am J Hematol. 2022;97:E232-E235.
     PubMed    
     
     
     June 2022
260. ALCAZER V, Bonaventura P, Tonon L, Michel E, et al
     HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy.
     Am J Hematol. 2022 Jun 27. doi: 10.1002/ajh.26647.
     PubMed     Abstract available
     
     
     
261. NICHOLS ED, Jammal N, Chew S, Bryan J, et al
     Real-life incidence of thrombotic events in leukemia patients treated with ponatinib.
     Am J Hematol. 2022 Jun 27. doi: 10.1002/ajh.26645.
     PubMed    
     
     
     
262. JABBOUR E, Kantarjian H
     Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy and Monitoring.
     Am J Hematol. 2022 Jun 25. doi: 10.1002/ajh.26642.
     PubMed     Abstract available
     
     
     
263. DHOPESHWARKAR N, Yang W, Hennessy S, Rhodes JM, et al
     Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: a population-based cohort study.
     Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26632.
     PubMed    
     
     
     
264. JABBOUR EJ, Short NJ, Jain N, Jammal N, et al
     Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10(-4) and Higher.
     Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
     PubMed     Abstract available
     
     
     
265. TEFFERI A, Gangat N, Al-Kali A, Alkhateeb H, et al
     A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
     Am J Hematol. 2022 Jun 15. doi: 10.1002/ajh.26630.
     PubMed     Abstract available
     
     
     
266. BARON F, Labopin M, Tischer J, Ciceri F, et al
     Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients >/=55 years of age.
     Am J Hematol. 2022 Jun 13. doi: 10.1002/ajh.26627.
     PubMed     Abstract available
     
     
     May 2022
267. PAUL S, Kantarjian H, Sasaki K, Marx K, et al
     Intrathecal Prophylaxis with 12 Versus 8 Administrations Reduces the Incidence of Central Nervous System Relapse in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
     Am J Hematol. 2022 May 28. doi: 10.1002/ajh.26622.
     PubMed    
     
     
     
268. BEELEN DW, Stelljes M, Remenyi P, Wagner-Drouet EM, et al
     Treosulfan Compared with Reduced-Intensity Busulfan Improves Allogeneic Hematopoietic Cell Transplantation Outcomes of Older Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: Final Analysis of a Prospective Randomized Trial.
     Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26620.
     PubMed     Abstract available
     
     
     
269. VABRE C, Zelmat Y, Gauthier M, Pajiep M, et al
     Incident users of tyrosine kinase inhibitors in chronic myeloid leukemia patients: analysis of anticancer treatment trajectories - A French population-based study using the French national health data system.
     Am J Hematol. 2022 May 26. doi: 10.1002/ajh.26621.
     PubMed    
     
     
     
270. GAMBACORTI-PASSERINI C, Nicolini FE, Larson RA, Aroldi A, et al
     Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia.
     Am J Hematol. 2022 May 23. doi: 10.1002/ajh.26618.
     PubMed    
     
     
     
271. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
     Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.
     Am J Hematol. 2022 May 18. doi: 10.1002/ajh.26601.
     PubMed     Abstract available
     
     
     
272. JONAS BA, Wei AH, Recher C, DiNardo CD, et al
     Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
     Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26600.
     PubMed    
     
     
     
273. CHERNG HJ, Khwaja R, Kanagal-Shamanna R, Tang G, et al
     TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
     Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26595.
     PubMed     Abstract available
     
     
     
274. GOTTLIEB DJ, Sutrave G, Jiang W, Avdic S, et al
     Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant.
     Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26594.
     PubMed     Abstract available
     
     
     
275. SINGH A, Al-Kali A, Begna KH, Litzow MR, et al
     Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
     Am J Hematol. 2022;97:630-637.
     PubMed     Abstract available
     
     
     
276. WANG J, Zhang X, Zhou Z, Liu Y, et al
     A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
     Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
     PubMed     Abstract available
     
     
     
277. GORDON MJ, Ferrajoli A
     Unusual complications in the management of chronic lymphocytic leukemia.
     Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26585.
     PubMed     Abstract available
     
     
     April 2022
278. PEREZ-CARRETERO C, Hernandez-Sanchez M, Gonzalez T, Quijada-Alamo M, et al
     TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
     Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26578.
     PubMed     Abstract available
     
     
     
279. KIM K, Konopleva M, DiNardo CD, Borthakur G, et al
     Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
     Am J Hematol. 2022 Apr 12. doi: 10.1002/ajh.26572.
     PubMed     Abstract available
     
     
     
280. TANG B, Lee JB, Cheng S, Pan T, et al
     Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study.
     Am J Hematol. 2022 Apr 6. doi: 10.1002/ajh.26564.
     PubMed    
     
     
     
281. SASAKI K, Ravandi F, Kadia T, DiNardo C, et al
     Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia.
     Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26557.
     PubMed     Abstract available
     
     
     
282. INZOLI E, Aroldi A, Piazza R, Gambacorti-Passerini C, et al
     Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.
     Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26556.
     PubMed     Abstract available
     
     
     
283. LARSSON K, Soderling J, Hoglund M, Glimelius I, et al
     Cardiovascular disease in patients with chronic lymphocytic leukemia. A Swedish nationwide register study with matched comparators.
     Am J Hematol. 2022 Apr 5. doi: 10.1002/ajh.26558.
     PubMed    
     
     
     
284. MCLAUGHLIN N, Ruan G, Day CN, Harmsen WS, et al
     A population-based study of acute panmyelosis with myelofibrosis in the United States: 2004-2015.
     Am J Hematol. 2022;97:E144-E147.
     PubMed    
     
     
     March 2022
285. HADDAD FG, Sasaki K, Issa GC, Garcia-Manero G, et al
     Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors.
     Am J Hematol. 2022 Mar 31. doi: 10.1002/ajh.26550.
     PubMed     Abstract available
     
     
     
286. COOK L, Al-Yousuf H, Mohamedbhai S, Bain BJ, et al
     Hyposplenism in adult T-cell leukemia/lymphoma.
     Am J Hematol. 2022 Mar 26. doi: 10.1002/ajh.26547.
     PubMed    
     
     
     
287. TORELLI GF, Chiaretti S, Peragine N, Barberi W, et al
     Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.
     Am J Hematol. 2022 Mar 22. doi: 10.1002/ajh.26537.
     PubMed    
     
     
     
288. KRAKOW EF, Walter RB, Nathe JM, Perez T, et al
     Intensive Chemotherapy for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation.
     Am J Hematol. 2022 Mar 18. doi: 10.1002/ajh.26540.
     PubMed    
     
     
     
289. SMITH AC, Maze D, Xia D, Capo-Chichi JM, et al
     A t(6;14;9)(p22;q22;q34) Three-Way Translocation: Description of a Cytogenetically Visible Variant t(6;9) in Acute Myeloid Leukemia.
     Am J Hematol. 2022 Mar 16. doi: 10.1002/ajh.26534.
     PubMed    
     
     
     
290. GALLANT RE, Arroyo K, Bracci PM, Li S, et al
     Clinical characteristics of cytomegalovirus-positive pediatric acute lymphoblastic leukemia at diagnosis.
     Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26528.
     PubMed    
     
     
     
291. SHORT NJ, Macaron W, Konopleva M, Ravandi F, et al
     Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
     Am J Hematol. 2022 Mar 10. doi: 10.1002/ajh.26526.
     PubMed    
     
     
     
292. KENNEDY VE, Hui G, Azenkot T, Gaut D, et al
     Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.
     Am J Hematol. 2022 Mar 9. doi: 10.1002/ajh.26524.
     PubMed    
     
     
     
293. ORTIZ-MALDONADO V, Alonso-Saladrigues A, Espanol-Rego M, Martinez-Cibrian N, et al
     Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
     Am J Hematol. 2022 Mar 7. doi: 10.1002/ajh.26519.
     PubMed     Abstract available
     
     
     February 2022
294. MOSHREF RAZAVI H, Yu R
     Myeloid neoplasm with PDGFRB rearrangement, presenting as systemic mastocytosis-chronic eosinophilic leukemia.
     Am J Hematol. 2022 Feb 21. doi: 10.1002/ajh.26505.
     PubMed    
     
     
     
295. POMMERT L, Schafer ES, Malvar J, Gossai N, et al
     Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
     Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26510.
     PubMed     Abstract available
     
     
     
296. ARBER DA, Hasserjian RP, Orazi A, Mathews V, et al
     Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach.
     Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26503.
     PubMed    
     
     
     
297. BALL S, Jain AG, Aguirre LE, Al Ali N, et al
     Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?
     Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26504.
     PubMed    
     
     
     
298. SHI M, Li L, Wang S, Cheng H, et al
     Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia.
     Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26506.
     PubMed     Abstract available
     
     
     
299. MOLICA S, Giannarelli D, Visentin A, Reda G, et al
     Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
     Am J Hematol. 2022 Feb 16. doi: 10.1002/ajh.26502.
     PubMed    
     
     
     
300. SENAPATI J, Shoukier M, Garcia-Manero G, Wang X, et al
     Activity of Decitabine as Maintenance Therapy in Core Binding Factor Acute Myeloid Leukemia.
     Am J Hematol. 2022 Feb 12. doi: 10.1002/ajh.26496.
     PubMed     Abstract available
     
     
     
301. POURHASSAN H, Yang D, Afkhami M, Pillai R, et al
     High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.
     Am J Hematol. 2022 Feb 7. doi: 10.1002/ajh.26490.
     PubMed    
     
     
     
302. RACK K, De Bie J, Ameye G, Gielen O, et al
     Optimizing the Diagnostic Workflow for Acute Lymphoblastic Leukemia by Optical Genome Mapping.
     Am J Hematol. 2022 Feb 4. doi: 10.1002/ajh.26487.
     PubMed     Abstract available
     
     
     
303. ALLSUP DJ, Craig Z, Cairns D, Howard D, et al
     Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
     Am J Hematol. 2022 Feb 2. doi: 10.1002/ajh.26483.
     PubMed    
     
     
     
304. UJJANI C, Greninger AL, Shadman M, Hill JA, et al
     Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
     Am J Hematol. 2022;97:E67-E69.
     PubMed    
     
     
     
305. GAO F, Gao Y, Luo Y, Yu J, et al
     Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transpl
     Am J Hematol. 2022;97:E44-E47.
     PubMed    
     
     
     
306. KUNO M, Yamasaki S, Fujii N, Ishida Y, et al
     Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation.
     Am J Hematol. 2022;97:185-193.
     PubMed     Abstract available
     
     
     January 2022
307. SZUBER N, Elliott M, Tefferi A
     Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.
     Am J Hematol. 2022 Jan 28. doi: 10.1002/ajh.26481.
     PubMed     Abstract available
     
     
     
308. LAZARIAN G, Theves F, Hormi M, Letestu R, et al
     TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.
     Am J Hematol. 2022 Jan 26. doi: 10.1002/ajh.26479.
     PubMed    
     
     
     
309. IJURKO C, Gonzalez-Garcia N, Galindo-Villardon P, Hernandez-Hernandez A, et al
     A 29-gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival.
     Am J Hematol. 2022 Jan 24. doi: 10.1002/ajh.26477.
     PubMed     Abstract available
     
     
     
310. DORFMAN DM, Pinkus GS
     A case of peripheral T-cell lymphoma, NOS mimicking acute monocytic leukemia.
     Am J Hematol. 2022 Jan 22. doi: 10.1002/ajh.26476.
     PubMed    
     
     
     
311. ROSSI M, Nizzoli ME, Galli A, Roncoroni E, et al
     Sequential next generation sequencing analysis in homogeneously treated low risk NPM1-mutated acute myeloid leukemia with an adverse clinical outcome.
     Am J Hematol. 2022 Jan 18. doi: 10.1002/ajh.26469.
     PubMed    
     
     
     
312. DAHLEN T, Edgren G, Ljungman P, Flygt H, et al
     Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
     Am J Hematol. 2022 Jan 11. doi: 10.1002/ajh.26463.
     PubMed     Abstract available
     
     
     
313. JELLOUL FZ, Yang R, Wang P, Garces S, et al
     Non-Coding NOTCH1 Mutations in Chronic Lymphocytic Leukemia Negatively Impact Prognosis.
     Am J Hematol. 2022 Jan 6. doi: 10.1002/ajh.26457.
     PubMed    
     
     
     
314. PATNAIK MM, Tefferi A
     Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification and Management.
     Am J Hematol. 2022 Jan 5. doi: 10.1002/ajh.26455.
     PubMed     Abstract available
     
     
     
315. REVILLE PK, Sasaki K, Kantarjian HM, Daver NG, et al
     Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
     Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26451.
     PubMed     Abstract available
     
     
     
316. NUMAN Y, Abdel Rahman Z, Grenet J, Boisclair S, et al
     Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
     Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26447.
     PubMed     Abstract available
     
     
     
317. NAGLER A, Labopin M, Craddock C, Socie G, et al
     Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation.
     Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26442.
     PubMed     Abstract available
     
     
     
318. RIBEIL JA
     Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?
     Am J Hematol. 2022;97:4-6.
     PubMed    
     
     
     December 2021
319. DAVIDS MS, Shadman M, Parikh SA, Ujjani C, et al
     A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.
     Am J Hematol. 2021 Dec 20. doi: 10.1002/ajh.26444.
     PubMed    
     
     
     
320. VISENTIN A, Mauro FR, Cibien F, Vitale C, et al
     Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
     Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26437.
     PubMed    
     
     
     
321. SEGOT A, Stalder G, de Leval L, Solly F, et al
     Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia.
     Am J Hematol. 2021 Dec 14. doi: 10.1002/ajh.26436.
     PubMed    
     
     
     
322. FORTES BH, Dalvin LA, Hogan WJ, Patnaik MM, et al
     Isolated T-cell acute lymphoblastic leukemic optic disc infiltration.
     Am J Hematol. 2021;96:1717-1718.
     PubMed    
     
     
     November 2021
323. SANTOS FM, Ghelfond G, Seguro FS, Abdo ANR, et al
     Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia.
     Am J Hematol. 2021 Nov 25. doi: 10.1002/ajh.26424.
     PubMed    
     
     
     
324. POPOVIC R, Dunbar F, Lu C, Robinson K, et al
     Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
     Am J Hematol. 2021 Nov 14. doi: 10.1002/ajh.26411.
     PubMed    
     
     
     
325. CHO BS, Min GJ, Park SS, Yoon SY, et al
     Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
     Am J Hematol. 2021;96:1441-1449.
     PubMed     Abstract available
     
     
     October 2021
326. SASAKI K, Kadia T, Begna K, DiNardo CD, et al
     Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.
     Am J Hematol. 2021 Oct 30. doi: 10.1002/ajh.26395.
     PubMed     Abstract available
     
     
     
327. TROUSSARD X, Maitre E, Cornet E
     Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
     Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26390.
     PubMed     Abstract available
     
     
     
328. MUCHTAR E, Koehler AB, Johnson MJ, Rabe KG, et al
     Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
     Am J Hematol. 2021 Oct 26. doi: 10.1002/ajh.26388.
     PubMed     Abstract available
     
     
     
329. ZHANG Y, Li X, Weng X, Shen Y, et al
     Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: a single-arm, phase 2 trial (RJ-AML 2014).
     Am J Hematol. 2021 Oct 23. doi: 10.1002/ajh.26386.
     PubMed     Abstract available
     
     
     
330. HALLEK M, Al-Sawaf O
     Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
     Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26367.
     PubMed     Abstract available
     
     
     
331. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
     BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
     Am J Hematol. 2021;96:1195-1203.
     PubMed     Abstract available
     
     
     
332. GRIMM J, Jentzsch M, Bill M, Backhaus D, et al
     Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.
     Am J Hematol. 2021;96:1287-1294.
     PubMed     Abstract available
     
     
     September 2021
333. FURSTENAU M, Giza A, Stumpf T, Robrecht S, et al
     Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
     Am J Hematol. 2021 Sep 30. doi: 10.1002/ajh.26363.
     PubMed    
     
     
     August 2021
334. SALIBA AN, Litzow MR, Gangat N, Al-Kali A, et al
     Outcomes of Venetoclax-Based Therapy in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia.
     Am J Hematol. 2021 Aug 24. doi: 10.1002/ajh.26334.
     PubMed    
     
     
     
335. ZHOU B, Chu X, Tian H, Liu T, et al
     The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-year Retrospective Study.
     Am J Hematol. 2021 Aug 18. doi: 10.1002/ajh.26324.
     PubMed     Abstract available
     
     
     
336. ZHANG M, Xiao H, Shi J, Tan Y, et al
     Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: a phase III randomized controlled study.
     Am J Hematol. 2021 Aug 9. doi: 10.1002/ajh.26317.
     PubMed     Abstract available
     
     
     
337. ALWASH Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, et al
     Development of TP53 Mutations Over the Course of Therapy for Acute Myeloid Leukemia.
     Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.
     PubMed     Abstract available
     
     
     
338. CHEN Z, Song J, Wang W, Bai J, et al
     A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia.
     Am J Hematol. 2021 Aug 2. doi: 10.1002/ajh.26309.
     PubMed     Abstract available
     
     
     July 2021
339. VARETTONI M, Orlandi E, Zibellini S, Rossi M, et al
     Prognostic impact of somatic mutations on time to first treatment: results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
     Am J Hematol. 2021 Jul 30. doi: 10.1002/ajh.26302.
     PubMed    
     
     
     
340. KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
     Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
     Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.
     PubMed    
     
     
     
341. BROCCOLI A, Argnani L, Nanni L, Terragna C, et al
     The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a thirty-year experience.
     Am J Hematol. 2021 Jul 10. doi: 10.1002/ajh.26287.
     PubMed     Abstract available
     
     
     
342. GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
     Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
     Am J Hematol. 2021;96:781-789.
     PubMed     Abstract available
     
     
     
343. HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
     Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
     Am J Hematol. 2021;96:E259-E262.
     PubMed    
     
     
     
344. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
     Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
     Am J Hematol. 2021;96:E237-E239.
     PubMed    
     
     
     
345. JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
     A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
     Am J Hematol. 2021;96:E226-E229.
     PubMed    
     
     
     
346. OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
     Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
     Am J Hematol. 2021;96:E223-E225.
     PubMed    
     
     
     June 2021
347. JABBOUR E, Patel K, Jain N, Duose D, et al
     Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
     Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
     PubMed     Abstract available
     
     
     
348. LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
     Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
     Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
     PubMed    
     
     
     
349. MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
     Ruxolitinib for refractory large granular lymphocyte leukemia.
     Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.
     PubMed    
     
     
     
350. HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
     Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
     Am J Hematol. 2021;96:E187-E189.
     PubMed    
     
     
     May 2021
351. AL-SAWAF O, Gentile B, Devine J, Zhang C, et al
     Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
     Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26260.
     PubMed     Abstract available
     
     
     
352. PICIOCCHI A, Messina M, Elia L, Vitale A, et al
     Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.
     Am J Hematol. 2021 May 28. doi: 10.1002/ajh.26253.
     PubMed    
     
     
     
353. ST MARTIN EC, Ferrer A, Wudhikarn K, Mangaonkar A, et al
     Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes.
     Am J Hematol. 2021 May 24. doi: 10.1002/ajh.26250.
     PubMed    
     
     
     
354. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
     Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
     Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
     PubMed    
     
     
     
355. JAIN N, Maiti A, Ravandi F, Konopleva M, et al
     Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia.
     Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.
     PubMed     Abstract available
     
     
     
356. MORABITO F, Del Poeta G, Mauro FR, Reda G, et al
     TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
     Am J Hematol. 2021 May 14. doi: 10.1002/ajh.26235.
     PubMed    
     
     
     
357. HALL KH, Brooks A, Waller EK
     Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
     Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26231.
     PubMed    
     
     
     
358. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
     Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
     Am J Hematol. 2021;96:E168-E171.
     PubMed    
     
     
     
359. OTHMAN TA, Mei M, Zhang J, Aldoss I, et al
     Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
     Am J Hematol. 2021;96:E140-E143.
     PubMed    
     
     
     April 2021
360. KADIA TM, Ravandi F, Borthakur G, Konopleva M, et al
     Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
     Am J Hematol. 2021 Apr 26. doi: 10.1002/ajh.26206.
     PubMed     Abstract available
     
     
     
361. YILMAZ M, Daver N, Borthakur G, Kadia T, et al
     FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
     Am J Hematol. 2021 Apr 23. doi: 10.1002/ajh.26202.
     PubMed    
     
     
     
362. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
     Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
     Am J Hematol. 2021 Apr 20. doi: 10.1002/ajh.26201.
     PubMed    
     
     
     
363. JAMY O, Godby R, Sarmad R, Costa LJ, et al
     Survival of Chronic Myeloid Leukemia Patients in Comparison to the General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study.
     Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26195.
     PubMed    
     
     
     
364. PELLAND-MARCOTTE MC, Kulkarni K, Athale UH, Pole JD, et al
     Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C.
     Am J Hematol. 2021 Apr 13. doi: 10.1002/ajh.26193.
     PubMed     Abstract available
     
     
     
365. APEL A, Moshe Y, Ofran Y, Gural A, et al
     Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice.
     Am J Hematol. 2021 Apr 9. doi: 10.1002/ajh.26190.
     PubMed     Abstract available
     
     
     
366. DONG N, Castillo Tokumori F, Isenalumhe L, Zhang Y, et al
     Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases.
     Am J Hematol. 2021 Apr 5. doi: 10.1002/ajh.26183.
     PubMed     Abstract available
     
     
     
367. GANGAT N, Szuber N, Jawaid T, Hanson CA, et al
     Young platelet millionaires with essential thrombocythemia.
     Am J Hematol. 2021;96:E93-E95.
     PubMed    
     
     
     
368. PARDANANI A
     Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
     Am J Hematol. 2021;96:508-525.
     PubMed     Abstract available
     
     
     April 2020
369. OHANIAN M, Telouk P, Kornblau S, Albarede F, et al
     A heavy metal baseline score predicts outcome in acute myeloid leukemia.
     Am J Hematol. 2020;95:422-434.
     PubMed     Abstract available
     
     
     
370. COLTRO G, Antelo G, Lasho TL, Finke CM, et al
     Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
     Am J Hematol. 2020;95:E86-E89.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.